WO2008059965A1 - Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux - Google Patents

Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux Download PDF

Info

Publication number
WO2008059965A1
WO2008059965A1 PCT/JP2007/072297 JP2007072297W WO2008059965A1 WO 2008059965 A1 WO2008059965 A1 WO 2008059965A1 JP 2007072297 W JP2007072297 W JP 2007072297W WO 2008059965 A1 WO2008059965 A1 WO 2008059965A1
Authority
WO
WIPO (PCT)
Prior art keywords
coenzyme
agent
represented
chemical
following formula
Prior art date
Application number
PCT/JP2007/072297
Other languages
English (en)
Japanese (ja)
Inventor
Kenji Fujii
Mikio Kitahara
Original Assignee
Kaneka Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kaneka Corporation filed Critical Kaneka Corporation
Publication of WO2008059965A1 publication Critical patent/WO2008059965A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/111—Aromatic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K20/00—Accessory food factors for animal feeding-stuffs
    • A23K20/10—Organic substances
    • A23K20/105—Aliphatic or alicyclic compounds
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A61K31/09—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon having two or more such linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Definitions

  • the present invention relates to a stress symptom reducing agent, a preventive agent thereof, and a mental condition improving agent. Specifically, as a result of mental stress that occurs in everyday or extraordinary situations, a symptom-relieving or preventing agent for stress symptoms such as tension, and a mental state that improves the mental state for which improvement is desired It provides an improving agent.
  • the symptoms caused by mental stress include tension, irritability, hot flashes, insomnia, ilaila sensation, seizure, stuttering, mental fatigue, gastrointestinal disorders, gastric pain, alopecia, fear, helplessness In addition to weakness, loss of appetite, headache, and sore throat, each individual has various symptoms.
  • it is not clearly associated with mental stress, but in the mental state of daily life, it is angry, unmotivated, depressed, lack of happiness, lack of confidence, self-existence significance
  • mental states that are generally desired to be improved, such as lack of well-being, poorness, lack of concentration, melancholy, loss of life, unpleasantness, and depression.
  • Coenzyme Q is a force known from coenzyme Q1 to coenzyme Q13 due to the repeating structure of its side chain S.
  • coenzyme Q10 is the main coenzyme Q, and human Uses coenzyme Q10.
  • Coenzyme Q10 is mitochondria, lysosome, Golgi, micro Localized in the some, peroxisome, cell membrane, etc., it is an indispensable substance for maintaining the function of the living body involved in ATP production activation, in vivo antioxidant action, and membrane stabilization as a component of the electron transport system .
  • Coenzyme Q10 is known to be oxidized and reduced.
  • the oxidized form is named ubiquinone
  • the reduced form is named ubiquinol.
  • coenzyme Q is known to transfer electrons by repeating redox.
  • the antioxidative activity is shown only in the reduced form and coenzyme Q in vivo exists in many parts, it is thought that the reduced form is the main form.
  • reduced coenzyme Q has a problem in oxidative stability, only oxidized coenzyme Q has been used in the industry so far. From such a background, when there is a description of coenzyme Q, it is common to indicate oxidized coenzyme Q unless otherwise noted, and when referring to reduced form, ubiquinol or reduced coenzyme is indicated. Q is listed.
  • Oxidized coenzyme Q10 has heretofore been used as an adjuvant for congestive heart failure. In recent years, it has been widely used worldwide as a supplement. Its physiological activity has been extensively studied, and many physiological activities such as anti-diabetic, anti-fatigue and anti-arteriosclerosis are known (patent documents;! To 3). As an anti-stress effect of coenzyme Q10, it has been reported that when oxidized coenzyme Q10 is used in combination with octacosanol or ezukogi (Patent Documents 4 and 5), Is a response to the stress of physical cold, and the effect of coenzyme Q on mental stress that occurs in normal life was not known at all.
  • Patent Document 1 JP-A-7-330584
  • Patent Document 2 JP-A-7-330593
  • Patent Document 3 JP-A-10-287560
  • Patent Document 4 JP 2004-292355
  • Patent Document 5 JP-A-2004-210728
  • the present invention relates to foods, health foods, dietary supplements, supplements, pharmaceuticals, quasi-drugs, It is an object of the present invention to provide an agent for alleviating or preventing stress symptoms, or an agent for improving mental condition, and a composition containing the agent, which are useful as a food or feed.
  • the present invention provides a stress symptom relieving agent or preventive agent or mental condition improving agent characterized by comprising oxidized coenzyme Q and / or reduced coenzyme Q as an active ingredient, and It relates to foods, health foods, dietary supplements, supplements, pharmaceuticals, quasi-drugs, pet foods, or feed containing palliatives or preventives or mental condition improvers.
  • the present invention provides the following:
  • n an integer of 1 to 12
  • Oxidized coenzyme Q represented by the above formula (1) and / or reduction represented by the above formula (2) A mental condition improving agent characterized by comprising type coenzyme Q as an active ingredient.
  • Nutritional supplements are amino acids, metal ions, sugars, proteins, fatty acids, vitamins, vitamin B derivatives, theanine, ⁇ -aminobutyric acid (GABA), anserine, soy peptide, thioredoxin, wheat dartene hydrolysis , Glutamine, milk peptide, ⁇ -3 fatty acids, phosphatidylserine, wastaxanthin, polyphenols, green tea catechin, saponin, yew leaf extract, saint john's wort, rabu hemp extract, sorghum, coral rust, and rydanans
  • GABA ⁇ -aminobutyric acid
  • the agent according to [4] which is one or more selected from the group consisting of:
  • Antioxidant power group consisting of vitamin ⁇ , vitamin ⁇ derivatives, vitamin C, vitamin C derivatives, lycopene, vitamin A, carotenoids, vitamin B, vitamin B derivatives, flavonoids, astaxanthin, dartathione and selenium
  • the agent according to [7] which is at least one selected from the group consisting of:
  • Antioxidant power One or more selected from the group consisting of superoxide dismutase (SOD), dartathione peroxidase, dartathione S transferase, dartathione reductase, force tarase and ascorbate peroxidase [7] The agent according to [7].
  • SOD superoxide dismutase
  • dartathione peroxidase dartathione S transferase
  • dartathione reductase force tarase and ascorbate peroxidase
  • composition containing oxidized coenzyme Q represented by the above formula (1) and / or reduced coenzyme Q represented by the above formula (2) as active ingredients, and the composition as a stress A commercial package containing a statement stating that it should or should be used to alleviate or prevent symptoms or improve mental status.
  • the agent for alleviating or preventing stress symptoms or the mental condition improving agent of the present invention is excellent in improving the mental state in normal life as well as alleviating or preventing various symptoms caused by mental stress such as tension. It can be taken on a daily basis without any side effects such as sleepiness.
  • the composition containing the agent for alleviating or preventing stress symptoms or the mental condition improving agent of the present invention is useful as a food, health food, dietary supplement, supplement, pharmaceutical, quasi-drug, pet food, or feed. .
  • the stress symptom-reducing or preventing agent or mental condition-improving agent of the present invention (hereinafter sometimes referred to as the agent of the present invention) is an oxidized coenzyme Q represented by the following formula (1) and / or the following formula (2) A reduced coenzyme Q represented by the formula is used as an active ingredient.
  • the "stress symptom" in the present invention refers to various symptoms caused by mental stress, and is not limited and varies depending on individuals or individuals. Specifically, tension, irritability, hot flashes, insomnia, Easy to get angry, depressed, irritated, attracted, stuttering, mental fatigue, gastrointestinal disorders, stomach pain, hair loss, fear, helplessness, weakness, decreased motivation, loss of appetite, headache, throat, tics, dry skin Etc.
  • the agent for alleviating or preventing stress symptoms of the present invention has an action of alleviating the stress symptoms or preventing such symptoms from occurring.
  • Relieving stress symptoms in the present invention means that the above symptoms are subjectively or objectively normal (a state in which the above symptoms are not conscious or unintentional) or close to a normal state. Means. That is, the stress symptoms of an individual who is aware of the above symptoms in life, or who is judged to be in such a state as viewed from others, take (or ingest) the alleviating agent of the present invention. As a result, stress symptoms can be consciously or objectively improved.
  • the prevention of stress symptoms in the present invention refers to a situation in which a so-called stress is expected to occur under certain special circumstances, for example, when something is performed before a test or in front of another person. Or by taking (or ingesting) the preventive agent of the present invention on a daily basis. To prevent or reduce the incidence of symptoms (ie, reduce the risk of developing stress symptoms)!
  • the improvement of the mental state in the present invention is not clearly associated with stress, but the mental state generally desired to be improved in the mental state in daily life. I like it, I will improve it in the direction.
  • the mental states for which the above improvement is desired include anger, lack of motivation, depression, lack of happiness, lack of confidence, lack of self-existence significance, well-being, lack of concentration, anxiety, decline in purpose of life, Mental conditions such as unpleasant and depressed are listed.
  • the oxidized coenzyme Q used in the agent of the present invention can be obtained by a conventionally known method such as a fermentation method, a synthesis method, or an extraction method from animals or plants.
  • a method other than a synthesis method such as a certain force fermentation method is preferable from the viewpoint of safety, for example, Kaneiki's Coenzyme Q10 (trademark of Kane force).
  • the method for obtaining reduced coenzyme Q used in the agent of the present invention is not particularly limited.
  • reduced form in the effluent is obtained by chromatography.
  • a method of concentrating the coenzyme Q category can be employed.
  • a general reducing agent such as sodium borohydride or sodium dithionite (hydrosulfite sodium) is added to the above-mentioned coenzyme Q, and the above-mentioned supplementation is performed by a conventional method.
  • Concentration by chromatography may be performed after reducing the oxidized coenzyme Q contained in enzyme Q to reduce coenzyme Q.
  • oxidized coenzyme Q can be reduced to reduced coenzyme Q in the preparation by formulating oxidized coenzyme Q together with a substance having a reducing ability such as vitamins.
  • KANEKA QH Koreani Co., Ltd.
  • coenzyme Q which is a mixture of oxidized and reduced forms obtained by a known method, may be used as it is.
  • both oxidized coenzyme Q and reduced coenzyme Q are effective components. It can also be used as a fraction, and can also be coenzyme Q, which is a mixture of oxidized coenzyme Q and reduced coenzyme Q. In that case, the ratio of oxidized and reduced forms in coenzyme Q can be appropriately determined depending on the product receptacle. Increasing the ratio of reduced coenzyme Q in coenzyme Q can be expected to have a higher effect than the potential for cost increase due to stabilization measures.
  • the ratio of reduced coenzyme Q in coenzyme Q is preferably 20% or more. More preferably, it is more preferably 70% or more.
  • coenzyme Q when simply described as “coenzyme Q” in the present application, it means any of oxidized coenzyme Q alone, reduced coenzyme Q alone, and a mixture of oxidized and reduced forms.
  • the ratio of oxidized and reduced forms in coenzyme Q is usually determined by quantifying oxidized coenzyme Q and reduced coenzyme Q in a sample using an HPLC system using a UV detector. There are two methods, one is to calculate the ratio, and the other is to calculate the ratio of oxidized coenzyme Q and reduced coenzyme Q from the peak area using a system that incorporates an electrochemical detector in HPLC.
  • a system incorporating an electrochemical detector can measure redox substances specifically and has a high sensitivity V. Therefore, it is useful when measuring the proportion of reduced forms in living organisms or samples in trace amounts. high.
  • the ratios of oxidized coenzyme Q and reduced coenzyme Q shown in the present invention are not limited to this method, of course, the force quantified by an HPLC system incorporating an electrochemical detector! / ,.
  • coenzyme Q10 in which n is 10 as coenzyme Q.
  • coenzyme Q may be ingested as it is, but since coenzyme Q is fat-soluble, it is preferably dispersed and dissolved in general edible fats and oils.
  • edible oils and fats include vegetable oils, processed oils and fats, animal fats and oils, and specifically, rice oil, rapeseed oil, palm oil, coconut oil, corn oil, safflower oil, and cottonseed oil.
  • the agent of the present invention can contain both nutritional supplements, health food ingredients, and more general food ingredients.
  • Nutritional supplements are not particularly limited! /, But amino acids, metal ions, sugars, proteins, fatty acids, vitamins such as vitamin B derivatives, theanine, ⁇ -aminobutyric acid (GAB A ), Anserine, soy peptide, thioredoxin, wheat dartene hydrolyzate, dartamine, milk peptide, docosahexaenoic acid, eicosapentaenoic acid and other ⁇ -3 fatty acids, phosphatidylserine, wastaxanthin, polyphenols, green tea catechins, And lignans such as saponin, Ichiyo leaf extract, St. John's wort, Rafu hemp extract, Yezogigi, shark rust and sesamin.
  • GAB A ⁇ -aminobutyric acid
  • lignans such as saponin, Ichiyo leaf extract, St. John's wort, Rafu hemp extract, Yezogigi, shark rust and sesamin.
  • the health food material is not particularly limited, and examples thereof include herbs, herbal medicines, mushrooms, and extracts thereof.
  • Herbs include, for example, Italian parsley, Erikampain, Olive, Olegano, Carldon, Power Fir Nore, Curry Plant, Cat Yuff.
  • Herbal medicines include, for example, akaneko, Akiyo, Akebei, Azenak, Ikarisou, Isi, Ichiyo, Ilraysen, Chinkou, Wikiwe, Tucon, Usokkko, Uz, Unoku, Ujak, Duyoyo, Engosaku, Ougi, Ogon, Ousei, Obata, Oulen, Ootsafuji, Obaco, Onji, Kai Power, Kaikinsha, Kaigoshii, Kaituhi, Geiha Kagoso, oak, oak yu, gadju, katsukou, katsukon, katsuki, kayak, carocon, caronine, kankyoyou, forceonulo, kanrenso, kikiyou, chrysanthemum, kikukoku, pheasant, yellowfin, kiban, giyukaku, kiyoukatsu, kiyoukoku Kinshi Ushi, G
  • the agent of the present invention may contain both an antioxidant and an antioxidant enzyme.
  • Antioxidants are not particularly limited.
  • the antioxidant enzyme is not particularly limited, and examples thereof include superoxide dismutase (SOD), glutathione peroxidase, glutathione S-transferase, glutathione reductase, catalase, and ascorbate peroxidase. It is done.
  • SOD superoxide dismutase
  • glutathione peroxidase glutathione S-transferase
  • glutathione reductase glutathione reductase
  • catalase catalase
  • ascorbate peroxidase catalase
  • antioxidant substances one or two or more kinds of antioxidant substances, antioxidant enzymes, nutritional supplements, and health food materials as exemplified above can be used as appropriate.
  • ingredients that are pharmaceutically acceptable or acceptable as foods may be appropriately added to and mixed with the agent of the present invention by conventional methods.
  • Such materials are not particularly limited, and examples thereof include excipients, disintegrants, lubricants, binders, antioxidants, colorants, anti-aggregation agents, absorption promoters, solubilizers, and stabilization. And nourishing tonic ingredients.
  • the excipient is not particularly limited, and examples thereof include sucrose, lactose, glucose, corn starch, mannitol, crystalline cellulose, calcium phosphate, and calcium sulfate.
  • the disintegrant is not particularly limited, and examples thereof include starch, agar, calcium citrate, calcium carbonate, sodium hydrogen carbonate, dextrin, crystalline cellulose, carboxymethyl cellulose, tragacanth and the like.
  • the lubricant is not particularly limited, and examples thereof include talc, magnesium stearate, polyethylene glycol, silica, hydrogenated vegetable oil, and the like.
  • the binder is not particularly limited, and for example, ethyl cellulose, methyl cellulose, hydroxypropyl methyl cellulose, tragacanth, shellac, gelatin, gum arabic, polybulur pyrrolidone, polybullic alcohol, polyacrylic acid, polymethacrylic acid.
  • examples include acids and sorbitol.
  • the antioxidant is not particularly limited, and for example, ascorbic acid, tocopherolole
  • the colorant is not particularly limited. For example, it is permitted to be added to a pharmaceutical product.
  • the aggregation inhibitor is not particularly limited, and examples thereof include stearic acid, talc, light anhydrous caustic acid, and hydrous caustic dioxide.
  • the absorption promoter is not particularly limited, and examples thereof include higher alcohols, higher fatty acids, and surfactants such as lecithin, lysolecithin, and glycerin fatty acid ester.
  • the dissolution aid is not particularly limited, and examples thereof include organic acids such as fumaric acid, succinic acid, and malic acid.
  • the stabilizer is not particularly limited, and examples thereof include benzoic acid, sodium benzoate, paraethyl benzoate, and the like.
  • the nourishing tonic component is not particularly limited, and examples thereof include creatine, taurine, vitamin Bl, vitamin koji derivatives, amino acids, and mixtures of these substances.
  • the agent of the present invention can be used as it is or as a composition containing the same for foods, health foods, dietary supplements, supplements, pharmaceuticals, quasi drugs, pet foods, or feeds.
  • health food refers to all forms of food that can be ingested for health maintenance other than pharmaceuticals, such as health foods, health supplements, foods for specified health use, and functional nutrition foods.
  • the food is a so-called health food, the form of ingested unit amount per meal of oxidized coenzyme Q and / or reduced coenzyme Q If the food is a healthy drink, the coenzyme Q is suspended or dissolved in the bottle, etc. A form is mentioned.
  • the ingestion unit amount per meal is the amount of active ingredient ingested in the case of food.
  • the intake of the whole food varies from person to person, and it is difficult to define it as the content of the active ingredient in the composition. Therefore, taking into account the effective intake per day described below. Therefore, it is recommended to specify as a single intake of active ingredient.
  • the single intake is an amount that varies depending on age, weight, sex, degree of stress, and the like.
  • examples include a packaged form containing a single intake, that is, the amount of an active ingredient administered at a time, and a form that is contained in a bottle or the like in the form of a single drink.
  • the form of the agent of the present invention or a composition containing the agent is not particularly limited, but it is oral, such as capsules, microcapsules, soft capsules, tablets, powders, wearables, syrups, liquids, etc.
  • Edible oil and fat composition cooking oil, spray oil, butters, margarines, shortenings, whipped cream, concentrated milk, whiteners, dressings, pickle liquids, breads, Cakes, pies, cookies, Japanese confectionery, snacks, oil confectionery, chocolate and chocolate confectionery, rice confectionery, roux, sauces, sauces, toppings, ice confectionery, rice cakes, bakery mixes, Frozen foods, processed meat products, marine products, frozen entrées, livestock frozen foods, frozen foods such as agricultural frozen foods, cooked rice , Jams, cheese, cheese foods, cheese-like foods, gums, candies, fermented milk, canned foods, beverages, etc .; forms useful foods through skins such as patches, lotions, sprays The form to send to
  • the effective daily intake of the composition containing the agent of the present invention for humans (adults) is 10 to 500 mg, preferably 50 to 300 mg, more preferably as the amount of reduced coenzyme Q10. Is 50 ⁇ 200mg. When the intake is 50 mg or more, sufficient relief of symptoms caused by stress, prevention, and improvement of mental status can be obtained.
  • the effective ingestion amount is 50 to 1000 mg, preferably 100 to 600 mg, more preferably ⁇ (or 200 to 350 mg as the amount of oxidized coenzyme Q 10.
  • the above intake can be taken once or divided into several times a day. However, it is usually 2 weeks or longer, preferably 1 month or longer, especially when taking it as a prophylactic agent for stress symptoms, before the situation where stress symptoms are expected to occur. It is preferable to take it for at least one week.
  • coenzyme Q Since coenzyme Q is not accumulative, the effect of the agent of the present invention is attenuated by terminating the intake. Therefore, it is preferable to take it on a daily basis during periods when stress symptoms are alleviated and mental conditions are expected to be improved or when stress symptoms are expected to occur.
  • the agent of the present invention is used in humans and animals other than humans (eg, mammals other than humans (domestic animals such as pigs, horses, horses, dogs, cats, pets), birds such as chickens, etc.) It can be used to alleviate or prevent the above stress symptoms or to improve mental status.
  • mammals other than humans domestic animals such as pigs, horses, horses, dogs, cats, pets
  • birds such as chickens, etc.
  • the present invention provides a method for alleviating or preventing the stress symptoms or a method for improving mental state.
  • the method comprises a subject to be administered the above-mentioned alleviation, prevention or improvement (for example, human or non-human animal), preferably a subject to be aware of or aware of the stress symptoms on a daily basis!
  • a step of administering an effective amount of oxidized coenzyme Q represented by the above formula (1) and / or reduced coenzyme Q represented by the above formula (2) to an administration subject whose mental condition is desired to be improved including.
  • the present invention further provides a commercial package for performing the above method.
  • the commercial package includes an oxidized coenzyme Q represented by the above formula (1) and / or a reduced coenzyme Q represented by the above formula (2).
  • Relaxation Or a statement eg, instructions for carrying out the above method) that states that it can (or should be) used for prevention or improvement of mental status.
  • the present invention provides an oxidized coenzyme Q and / or the above-described formula (1) for producing an agent for alleviating or preventing stress symptoms, or an agent for improving mental state.
  • the use of reduced coenzyme Q represented by formula (2) is provided.
  • Example 1 Be aware of stress! // There is tension of oxidized coenzyme Q10 for healthy people! /, Is a mental stress alleviating effect
  • VAS visual alanog scale
  • the degree of awareness stress is evaluated by measuring the length from the left edge of the minute. Twenty-six volunteers were divided into two groups. Oxidized coenzyme Q10 capsules (test food) or placebo capsules (control food) with the formulation shown in Table 1 were administered daily for 2 weeks a week.
  • Oxidized coenzyme Q 10 KANEKI Co., Ltd.
  • Safflower oil Nisshin Oiliognolep Co., Ltd.
  • Poem S-100 Glycerin fatty acid ester surfactant, manufactured by Riken Vitamin Co., Ltd. Soy lecithin: manufactured by Sakai Oil Co., Ltd.
  • Table 2 shows the VAS results.
  • the oxygenated coenzyme Q10 intake group there was a statistically significant (p ⁇ 0. 05) relaxation in tension and irritability, and a relaxation tendency (p ⁇ 0.5) in subjective stress and throating. Admitted.
  • p ⁇ 0. 05 the oxygenated coenzyme Q10 intake group
  • p ⁇ 0.5 a relaxation tendency in subjective stress and throating.
  • ATMT performance showed a significant reduction in reaction time, indicating that the intake of oxidized coenzyme Q10 increases the work efficiency.
  • Conventional anti-stress substances often have a sedative effect that reduces performance, which is a problem in actual use.
  • Oxidized coenzyme Q10 3.64 ⁇ 1. 39 3.05 ⁇ 1.59 ** Ilila feeling Placebo 3.63 ⁇ 1.60 3.53 ⁇ 1.51
  • Oxidized coenzyme Q10 3.88 Sat 1. 55 3.07 ⁇ 1.75 ** Subjective stress Placebo 4.09 ⁇ 1.67 3.66 ⁇ 1.77
  • Oxidized coenzyme Q10 4.29 ⁇ 1. 83 3.26 ⁇ 1.74 * Throat Placebo 5.14 ⁇ 1.59 4.79 ⁇ 1.68
  • Oxidized coenzyme Q10 4.97 ⁇ 1.39 4.51 ⁇ 1.61 * Sleeping placebo 4.80 ⁇ 1.46 4.32 ⁇ 1.88
  • Oxidized coenzyme Q10 4.86 ⁇ 1.59 4.23 ⁇ 1.85 Motivation Placebo 4.96 ⁇ 1.24 4.79 ⁇ 1.36
  • Oxidized coenzyme Q10 4.86 ⁇ 1.17 4.61 Sat 1 ⁇ 59 Boring degree Placebo 3.74 ⁇ 1.26 3.57 ⁇ 1.76
  • Oxidized coenzyme Q10 3.96 ⁇ 1.52 3.55 ⁇ 1.70
  • Example 2 Be aware of stress! /, There is tension of reduced coenzyme Q10 for healthy people! /, Is a mental stress alleviating effect
  • Reduced coenzyme Q10 is known to have better oral absorption than oxidized coenzyme Q10, so a preliminary study was conducted, and blood concentration was the same as when 200 mg of oxidized coenzyme Q10 was ingested. The daily intake was set at 50 mg. As a result, similar results were obtained as when 200 mg of oxidized coenzyme Q10 was ingested. Specifically, a statistically significant relaxation was observed in the degree of tension, irritability and subjective stress. An improvement in performance was observed. On the other hand, there was no difference in sleepiness, motivation and boredom between the reduced coenzyme Q 10 intake group and the placebo group. This result is the result of reduced complement Stress relief effect of enzyme Q 10 S, indicating that it is highly useful without sedation, and comparable effect at lower doses compared to oxidized coenzyme Q 10 I have proved that.
  • Test meal composition table (4- oval soft force per capsule)
  • Safflower oil Nisshin Oiliognolep Co., Ltd.
  • Poem S-100 glycerin fatty acid ester surfactant, manufactured by Riken Vitamin Co., Ltd. soybean lecithin: manufactured by Sakai Oil Co., Ltd.
  • the improvement rate is the percentage of subjects who scored 2 or more before taking the capsule (subjects who are expected to improve their mental state) in each item. This is the percentage of subjects whose score was lower than before ingestion.
  • Oxidized coenzyme Q10 was dissolved in propanol, then adsorbed on microcrystalline cellulose, and dried under reduced pressure. This was mixed with corn starch under a nitrogen stream to obtain a powder.
  • Oxidized coenzyme Q 10 50 parts by weight
  • Oxidized coenzyme Q10 was dissolved in propanol, adsorbed on microcrystalline cellulose, and dried under reduced pressure.
  • corn starch, lactose, carboxymethylcellulose calcium and magnesium stearate were mixed under a nitrogen atmosphere, and then an aqueous solution of polyburpi-lididone was added as a binder and granulated by a conventional method. After adding and mixing with this as a lubricant, it was compressed into tablets. Tablets were packed in a nitrogen atmosphere and stored refrigerated.
  • Reduced coenzyme Q10 (containing 2% oxidized coenzyme Q10) was dissolved in propanol, then adsorbed onto microcrystalline cellulose, and dried under reduced pressure. This was mixed with corn starch under a nitrogen stream to obtain a powder.
  • a powder was prepared according to the following formulation, and then filled into gelatin capsules by a conventional method.
  • the filled capsules were sealed and then packed in a nitrogen atmosphere and stored refrigerated.
  • Corn oil was heated to 50 ° C, and reduced coenzyme Q10 (including 2% oxidized coenzyme Q10) melted at the same temperature was added and dissolved. This was soft-encapsulated by a conventional method.
  • Reduced coenzyme Q10 (containing 2% oxidized coenzyme Q10) was dissolved in propanol, adsorbed onto microcrystalline cellulose, and dried under reduced pressure. Nitrogen atmosphere Below, corn starch, lactose, carboxymethylcellulose calcium and magnesium stearate were mixed and granulated by a conventional method by adding an aqueous solution of polybulurpyrrolidone as a binder. This was mixed with talc as a lubricant, and then compressed into tablets. The tablets were stored refrigerated under a nitrogen atmosphere.
  • a powder was prepared according to the following formulation, and then filled into gelatin capsules by a conventional method.
  • the filled capsules were sealed and then packed in a nitrogen atmosphere and stored refrigerated.
  • Vitamin B 20 parts by weight
  • Vitamin B 20 parts by weight
  • a powder was prepared according to the following formulation in the same manner as in Formulation Example 1, and then filled with a conventional method.
  • the filled capsules were sealed and stored refrigerated under a nitrogen atmosphere.
  • a powder was prepared according to the following formulation in the same manner as in Formulation Example 1, and then filled with a conventional method.
  • the filled capsules were sealed and stored refrigerated under a nitrogen atmosphere.
  • Oxidized coenzyme Q10 and sesamin were dissolved in propanol, then adsorbed to a microcrystalline cell mouth, and then dried under reduced pressure. This was mixed with corn starch under a nitrogen stream to obtain a powder.
  • Reduced coenzyme Q10 (including 2% oxidized coenzyme Q10) and sesamin were dissolved in propanol, then adsorbed to microcrystalline cellulose, and then dried under reduced pressure. This was mixed with corn starch under a nitrogen stream to obtain a powder.
  • Corn oil was heated to 50 ° C, and dissolved by adding oxidized coenzyme Q10 and licorice extract melted at the same temperature. This is ordinary
  • Corn oil was heated to 50 ° C., and reduced coenzyme Q10 (containing 2% oxidized coenzyme Q10) melted at the same temperature and licorice extract were added and dissolved. This was soft-encapsulated by a conventional method.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Animal Husbandry (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Feed For Specific Animals (AREA)
  • Fodder In General (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

L'invention porte sur un agent destiné à soulager ou prévenir des symptômes de stress provoqués par un stress mental tel qu'une contrainte ou sur un agent afin d'améliorer des états mentaux, caractérisé par le fait qu'ils contiennent une coenzyme oxydée Q et/ou une coenzyme réduite Q en tant qu'ingrédient actif ; et sur un aliment, un aliment sain, un aliment de supplément nutritionnel, un supplément, un médicament, un quasi-médicament, un aliment pour animaux domestiques ou une alimentation contenant l'agent pour soulager ou prévenir des symptômes de stress ou l'agent pour améliorer des états mentaux.
PCT/JP2007/072297 2006-11-17 2007-11-16 Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux WO2008059965A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006-311670 2006-11-17
JP2006311670A JP2010030901A (ja) 2006-11-17 2006-11-17 ストレス症状の緩和または予防剤

Publications (1)

Publication Number Publication Date
WO2008059965A1 true WO2008059965A1 (fr) 2008-05-22

Family

ID=39401768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/072297 WO2008059965A1 (fr) 2006-11-17 2007-11-16 Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux

Country Status (3)

Country Link
JP (1) JP2010030901A (fr)
TW (1) TW200838496A (fr)
WO (1) WO2008059965A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101658233B (zh) * 2009-09-07 2011-10-05 汕头市新特医药有限公司 一种压片糖果及其制造方法
US20110268717A1 (en) * 2010-04-29 2011-11-03 Betul Hatipoglu Herbal-Based Compositions for Alleviating Symptoms Associated with Autism
WO2020085155A1 (fr) * 2018-10-26 2020-04-30 サントリーホールディングス株式会社 Composition orale contenant une coenzyme q10 réduite, son procédé de production, procédé de prévention de décoloration et agent de prévention de décoloration

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5364580B2 (ja) * 2007-08-22 2013-12-11 株式会社カネカ 還元型補酵素ｑ１０の製造方法、ならびに、その安定化方法
KR101656224B1 (ko) 2011-10-12 2016-09-09 포-데이즈 가부시키가이샤 시스테인 펩티드 함유 건강 음료
KR101534406B1 (ko) * 2013-10-29 2015-07-09 경남과학기술대학교 산학협력단 열 스트레스 저감 사료첨가제 제조방법
WO2019188868A1 (fr) 2018-03-27 2019-10-03 森永乳業株式会社 Composition anti-stress
KR102544229B1 (ko) * 2021-12-15 2023-06-16 아주대학교산학협력단 천연물 추출혼합물을 포함하는 항스트레스용 조성물 내지 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004210728A (ja) * 2003-01-06 2004-07-29 Nonogawa Shoji Kk 抗ストレス剤
JP2004292355A (ja) * 2003-03-27 2004-10-21 Nonogawa Shoji Kk 抗ストレス剤
WO2005089740A1 (fr) * 2004-03-23 2005-09-29 Kaneka Corporation Composition de conenzyme q ayant une persistance à long terme dans le sang

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004210728A (ja) * 2003-01-06 2004-07-29 Nonogawa Shoji Kk 抗ストレス剤
JP2004292355A (ja) * 2003-03-27 2004-10-21 Nonogawa Shoji Kk 抗ストレス剤
WO2005089740A1 (fr) * 2004-03-23 2005-09-29 Kaneka Corporation Composition de conenzyme q ayant une persistance à long terme dans le sang

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SUZUKI Y. ET AL.: "Diabetes Mellitus Associated with 3243 Mitochondrial tRNA Leu(UUR) Mutation: Clinical Features and Coenzyme Q10 Treatment", MOLECULAR ASPECTS OF MEDICINE, vol. 18, no. SUPPL., 1997, pages S181 - S188, XP003022547 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101658233B (zh) * 2009-09-07 2011-10-05 汕头市新特医药有限公司 一种压片糖果及其制造方法
US20110268717A1 (en) * 2010-04-29 2011-11-03 Betul Hatipoglu Herbal-Based Compositions for Alleviating Symptoms Associated with Autism
US8828453B2 (en) * 2010-04-29 2014-09-09 Betul Hatipoglu Herbal-based compositions for alleviating symptoms associated with autism
WO2020085155A1 (fr) * 2018-10-26 2020-04-30 サントリーホールディングス株式会社 Composition orale contenant une coenzyme q10 réduite, son procédé de production, procédé de prévention de décoloration et agent de prévention de décoloration
JPWO2020085155A1 (ja) * 2018-10-26 2021-09-16 サントリーホールディングス株式会社 還元型コエンザイムｑ１０を含む経口用組成物、その製造方法、変色抑制方法及び変色抑制剤
JP7350770B2 (ja) 2018-10-26 2023-09-26 サントリーホールディングス株式会社 還元型コエンザイムｑ１０を含む経口用組成物、その製造方法、変色抑制方法及び変色抑制剤
TWI834743B (zh) * 2018-10-26 2024-03-11 日商三得利控股股份有限公司 含還原型輔酶ｑ１０之經口用組成物、其製造方法、變色抑制方法及變色抑制劑

Also Published As

Publication number Publication date
TW200838496A (en) 2008-10-01
JP2010030901A (ja) 2010-02-12

Similar Documents

Publication Publication Date Title
JP5546087B2 (ja) 皮膚疾患経口治療または予防剤
JPWO2008093793A1 (ja) 口腔内乾燥症の緩和または予防剤
EP1283038B1 (fr) Compositions permettant de regulariser le rythme circadien
WO2008059965A1 (fr) Agent pour soulager ou prévenir des symptômes de stress et agent pour améliorer des états mentaux
JP5119509B2 (ja) 活動意欲向上剤
WO2006059730A1 (fr) Préparation pour réduction de la graisse corporelle
JP2014019660A (ja) 活性酸素抑制剤
JP2006347927A (ja) 疲労改善剤
JP2016199491A (ja) 気分状態改善剤
JP2008143811A (ja) 脂質代謝促進組成物
US20090098097A1 (en) Composition for normalizing blood pressure
JP5103374B2 (ja) 心機能不良改善剤または心機能維持剤
WO2016135482A1 (fr) Compositions comprenant de la co-enzyme q10, de l'huile de krill et de la vitamine d
JP6203320B2 (ja) 皮膚疾患経口治療または予防剤
WO2019181822A1 (fr) Composition pour accélérer le métabolisme énergétique
JP6912214B2 (ja) 赤血球機能向上剤
Rao et al. A review on dietary supplements: Delivery systems, applications and regulations
JP2012082226A (ja) 皮膚疾患経口治療または予防剤
JP5735576B2 (ja) コエンザイムｑ１０を含有する組成物
JP2006137730A (ja) 抗疲労作用剤又は持久力増強剤、機能性食品又は化粧料
JP6462790B2 (ja) 皮膚疾患経口治療または予防剤
JP4997514B2 (ja) 血圧上昇抑制剤
JP2017057144A (ja) 口腔内乾燥症の緩和又は予防剤、予防製品及び処置方法
JP6214474B2 (ja) 皮膚疾患経口治療または予防剤
JP2004292355A (ja) 抗ストレス剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07832027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07832027

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP